Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cetuximab for metastatic colorectal cancer (mCRC), from ASCO 2008

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 27 Nov 2008

Views: 16002

Rating:

Save

Professor Carsten Bokemeyer

Categories:
Colorectal & gastro

Related Videos

Trifluridine/tipiracil plus bevacizumab provides a significant OS in mCRC

Dr Josep Tabernero - Vall d’Hebron University Hospital, Barcelona, Spain

Trifluridine/tipiracil plus bevacizumab provides a significant OS in mCRC ( Dr Josep Tabernero - Vall d’Hebron University Hospital, Barcelona, Spain )

Navigating evidence-based care with limited resources in Africa

Dr Verna Vanderpuye - National center for Radiotherapy and Nuclear Medicine...

Navigating evidence-based care with limited resources in Africa ( Dr Verna Vanderpuye - National center for Radiotherapy and Nuclear Medicine, Accra, Ghana )

Exploring prevention and early detection of cancer to the Choosing Wisely...

Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda

Exploring prevention and early detection of cancer to the Choosing Wisely initiative ( Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda )

Choosing Wisely in implementing prevention, screening and early detection...

Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda

Choosing Wisely in implementing prevention, screening and early detection programs in Africa ( Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda )

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy...

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for...

Dr Tanuj Chawla and Dr Giovanni Selvaggi

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer ( Dr Tanuj Chawla and Dr Giovanni Selvaggi )

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and...

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates...

Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates in resected stage I-III colorectal cancer ( Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA )

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not...

Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure ( Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK )

More from ecancer